Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985554 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02985554 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 3 participants.
The verdict
NCT02985554, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic stem cell transplantation. Approximately 29 patients will be enrolled, where about 6-12 patients will be included on the dose escalation phase and 20 patients will be on the expansion cohort at maximal tolerated dose.
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2020-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985554
The ClinicalTrials.gov registry entry for NCT02985554 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02985554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985554 about?
NCT02985554 is a clinical study titled "Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies". This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic stem cell transplantation. Approximately 29 patients will be enrolled, wh...
What is the current status of trial NCT02985554?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-03-20. Estimated completion is 2020-06-22.
What interventions are being tested in trial NCT02985554?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02985554?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.